Changes in T cell populations and concomitant perturbation of T cell effector functions have been postulated to account for many aging-related immune dysfunctions. Here, we report that high frequencies of CD28 null CD4؉ T cells were found in elderly individuals. Because deviations in the function of these unusual CD4؉ T cells might be directly related to CD28 deficiency, we examined the molecular basis for the loss of CD28 expression in CD4؉ T cells. In reporter gene bioassays, the minimal promoter of the CD28 gene was mapped to the proximal 400 base pairs (bp) of the 5 untranslated region. CD28 deficiency was associated with the loss of two noncompeting binding activities within a 67-bp segment of the minimal promoter. These binding activities were not competed by consensus Ets, Elk, or AP3 motifs that were found within the sequence stretch. The DNA-protein complexes were also not recognized by antibodies to Ets-related transcription factors. Furthermore, introduction of mutations into the 67-bp segment at positions corresponding to the two DNA-protein interaction sites, i.e. nucleotides spanning ؊206 to ؊179 and ؊171 to ؊148, resulted in the loss of specific nuclear factor binding activities and the abrogation of promoter activity. These observations implicate at least two regulatory motifs in the constitutive expression of CD28. The loss of binding activity of transacting factors specific for these sequences may contribute to the accumulation CD4؉CD28 null T cells during aging.

Despite a lack of robust evidence, anti-TNF therapies are in wide use for the treatment of noninfectious ocular inflammatory diseases. There is a clear rationale, based on mechanistic and preclinical efficacy data, for their use in posterior segment intraocular inflammation. However, their increasing use for other indications has been largely extrapolated from the benefit observed in autoinflammatory and autoimmune systemic diseases. Given their cost and the potential for significant adverse events, this review highlights the evidence for their continued use, possibilities for switching anti-TNF agents, and ways of reducing the risk of therapy.

, but negatively for iron (Figure 2). At this point, the ibopamine drops were discontinued. Comment Bacterial organisms can produce condition that promotes adrenochrome autoxidation. An acidic environment is created by the formation of lactic acid as the major metabolic end-product of carbohydrate fermentation by S. viridans. In our patient, the concurrent infection with S. viridans may have facilitated the oxidation of ibopamine into its degradation products, resulting in the rapid pigment deposition in the cornea. It is also possible that the deposition would have occurred even without the favorable environment created by the infectious keratitis. Animal models have shown that for pigment deposition to occur, oxidized adrenochrome and a susceptible corneal surface must be present, 6 a condition satisfied by our patient's persistent epithelial defect. Thus, based on our observations, patients using topical ibopamine eye drops should be carefully monitored for pigment deposition in the cornea, particularly in the presence of a compromised epithelial surface.

No abstract

PurposeWe report a rare case of CRB1gene mutation in two siblings (sisters) affected with the exact same genetic mutation on both CRB1genes resulting in varying phenotypes.Case ReportCRB1gene mutation in this case has resulted in causing varying degrees of Leber congenital amaurosis (LCA) in both sisters with a more severe phenotype in the older sibling causing LCA-8 with retinitis pigmentosa spectrum in both eyes and a milder phenotype causing LCA-8 with less severe rod cone dystrophy in the younger sister.ConclusionIn summary, the mechanisms of varying phenotypes resulting from CRB1 genetic mutation are still not well understood. We concluded that the presence of different phenotypes associated with identical genotypic mutation of a single gene in siblings or in a family is important especially when dealing with retinal dystrophies.